These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 37310401)

  • 1. A novel prognostic signature contributes to precision treatment in colon adenocarcinoma with KRAS mutation.
    Dong W; Zhang H; Li Q; Guan N; Yun C; Zhao H; Zhang F; Zeng Z; Hu Y; Li Q; Yang J; Ma Z; Chen M; Xiao W
    Eur J Cancer Prev; 2023 Nov; 32(6):557-565. PubMed ID: 37310401
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A novel strategy for precise prognosis management and treatment option in colon adenocarcinoma with TP53 mutations.
    Niu L; Liu L; Cai J
    Front Surg; 2023; 10():1079129. PubMed ID: 36843983
    [TBL] [Abstract][Full Text] [Related]  

  • 3. To explore the prognostic characteristics of colon cancer based on tertiary lymphoid structure-related genes and reveal the characteristics of tumor microenvironment and drug prediction.
    Wang Z; Niu D
    Sci Rep; 2024 Jun; 14(1):13555. PubMed ID: 38867070
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of a glycolysis- and lactate-related gene signature for predicting prognosis, immune microenvironment, and drug candidates in colon adenocarcinoma.
    Liu C; Liu D; Wang F; Xie J; Liu Y; Wang H; Rong J; Xie J; Wang J; Zeng R; Zhou F; Peng J; Xie Y
    Front Cell Dev Biol; 2022; 10():971992. PubMed ID: 36081904
    [No Abstract]   [Full Text] [Related]  

  • 5. Construction of a novel choline metabolism-related signature to predict prognosis, immune landscape, and chemotherapy response in colon adenocarcinoma.
    Liu C; Liu D; Wang F; Liu Y; Xie J; Xie J; Xie Y
    Front Immunol; 2022; 13():1038927. PubMed ID: 36451813
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Glucose metabolism-based signature predicts prognosis and immunotherapy strategies for colon adenocarcinoma.
    Bai Z; Yan C; Nie Y; Zeng Q; Xu L; Wang S; Chang D
    J Gene Med; 2024 Jan; 26(1):e3620. PubMed ID: 37973153
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of a Four-Gene Metabolic Signature to Evaluate the Prognosis of Colon Adenocarcinoma Patients.
    Zheng Y; Wu R; Wang X; Yin C
    Front Public Health; 2022; 10():860381. PubMed ID: 35462848
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An Intratumor Heterogeneity-Related Signature for Predicting Prognosis, Immune Landscape, and Chemotherapy Response in Colon Adenocarcinoma.
    Liu C; Liu D; Wang F; Xie J; Liu Y; Wang H; Rong J; Xie J; Wang J; Zeng R; Zhou F; Xie Y
    Front Med (Lausanne); 2022; 9():925661. PubMed ID: 35872794
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predictive Models for Colon Adenocarcinoma Diagnosis, Prognosis, and Immune Microenvironment Based on 2 Hypoxia-Related Genes: KDM3A and ENO3.
    Kong C; Zheng L; Fang S; Chen M; Lin G; Qiu R; Zhao Z; Chen W; Song J; Yang Y; Ji J
    Technol Cancer Res Treat; 2023; 22():15330338231195494. PubMed ID: 37650153
    [No Abstract]   [Full Text] [Related]  

  • 10. Metabolism-related lncRNAs signature to predict the prognosis of colon adenocarcinoma.
    Sun Y; Liu B; Xiao B; Jiang X; Xiang JJ; Xie J; Hu XM
    Cancer Med; 2023 Mar; 12(5):5994-6008. PubMed ID: 36366731
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Construction and validation of a cuproptosis-related lncRNA signature as a novel and robust prognostic model for colon adenocarcinoma.
    Xu M; Mu J; Wang J; Zhou Q; Wang J
    Front Oncol; 2022; 12():961213. PubMed ID: 35965536
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A potential prognostic prediction model of colon adenocarcinoma with recurrence based on prognostic lncRNA signatures.
    Jin L; Li C; Liu T; Wang L
    Hum Genomics; 2020 Jun; 14(1):24. PubMed ID: 32522293
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of a prognostic model for personalized prediction of colon adenocarcinoma (COAD) patient outcomes using methylation-driven genes.
    Chen D; Zhang B; Kang K; Li L; Liao Y; Qing S; Di Y
    J Appl Genet; 2023 Dec; 64(4):713-721. PubMed ID: 37589877
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A novel signature model based on mitochondrial-related genes for predicting survival of colon adenocarcinoma.
    Gao H; Xing F
    BMC Med Inform Decis Mak; 2022 Oct; 22(1):277. PubMed ID: 36273131
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A novel enterocyte-related 4-gene signature for predicting prognosis in colon adenocarcinoma.
    Cheng X; Wei Y; Fu Y; Li J; Han L
    Front Immunol; 2022; 13():1052182. PubMed ID: 36532007
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A novel machine learning model based on ubiquitin-related gene pairs and clinical features to predict prognosis and treatment effect in colon adenocarcinoma.
    Liang L; Liu L; Mai S; Chen Y
    Eur J Med Res; 2023 Jan; 28(1):41. PubMed ID: 36681855
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic implications of ferroptosis-associated gene signature in colon adenocarcinoma.
    Miao YD; Kou ZY; Wang JT; Mi DH
    World J Clin Cases; 2021 Oct; 9(29):8671-8693. PubMed ID: 34734046
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of a novel prognostic signature composed of 3 cuproptosis-related transcription factors in colon adenocarcinoma.
    Zhou L; Zhang Y; Xu Y; Jiang T; Tang L
    Genes Genomics; 2023 Aug; 45(8):1047-1061. PubMed ID: 37318704
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Circadian Clock Genes Are Correlated with Prognosis and Immune Cell Infiltration in Colon Adenocarcinoma.
    He A; Huang Z; Zhang R; Lu H; Wang J; Cao J; Feng Q
    Comput Math Methods Med; 2022; 2022():1709918. PubMed ID: 35116071
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lactate Metabolism-Associated lncRNA Pairs: A Prognostic Signature to Reveal the Immunological Landscape and Mediate Therapeutic Response in Patients With Colon Adenocarcinoma.
    Xiao J; Wang X; Liu Y; Liu X; Yi J; Hu J
    Front Immunol; 2022; 13():881359. PubMed ID: 35911752
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.